Evidence map›Paper›PMID 38813708›Full record

ArticleHaematologica2024

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.

Giacomo Coltro, Giulio Capecchi, Margherita Maffioli, Francesco Mannelli, Barbara Mora, Alessandro Atanasio, Alessandra Iurlo, Chiara Maccari, Mirko Farina, Elena Nacca and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Giacomo ColtroDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Giulio CapecchiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Margherita MaffioliHematology Unit, ASST Sette Laghi, Ospedale di Circolo, Varese.
Francesco MannelliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Barbara MoraHematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan.
Alessandro AtanasioDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Alessandra IurloHematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan.
Chiara MaccariDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Mirko FarinaHematology Unit, ASST Spedali Civili di Brescia, Brescia.
Elena NaccaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Marianna CaramellaDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan.
Leonardo SignoriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Miriam BorellaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Lorenza BertùDepartment of Medicine and Surgery, University of Insubria, Varese.
Maria EspositoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Paola GuglielmelliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
Francesco PassamontiHematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan.
Alessandro Maria VannucchiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence. a.vannucchi@unifi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NitrilesPyrazolesPyrimidinesAgedFemaleHumansMaleMiddle AgedPrognosisTreatment OutcomeNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID38813708
PMCPMC11443372

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.